Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic testing currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone on a stable dosage for a minimum of 3 months.~2. Male or female patients aged 18 and above.~3. Provision of signed written informed consent.~4. Good general health.~5. Females of childbearing potential must have a negative pregnancy test initially and at all visits. Females who are engaging in sexual intercourse must be using a medically acceptable method of contraception (as defined in the protocol, section 10.5).~6. Plasma renin activity must be within the clinically acceptable range at screening (less than 1.5 times upper normal range).~Exclusion Criteria:~1. Co-morbid condition requiring daily administration of a medication that induces hepatic enzymes or interferes with the metabolism of glucocorticoids.~2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the normal range or elevated liver function tests (ALT or AST) \> 2 times the upper limits of normal.~3. Females who are pregnant or lactating.~4. Women taking an estrogen-containing oral contraceptive pill and who have taken it within 6 weeks of recruitment.~5. Patients taking spironolactone.~6. Patients on inhaled or oral steroids apart from treatment for CAH.~7. Patients with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the trial.~8. Participation in another clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study.~9. Patients with history of bilateral adrenalectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone Modified Release Capsules (Type: EXPERIMENTAL): Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response

Based on this trial design, predict the completion outcome and termination type (if applicable).